SYNACT PHARMA ApS: Financial statements 2013
CVR: 34459975
Source: annual report 2013, Danish Business Authority
01/01/2013 – 31/12/2013
SYNACT PHARMA ApS (CVR 34459975) has filed annual accounts for 2013. In 2013, the company reported a gross profit of DKK -952,851 and a net result of DKK -1,061,402. Equity in the 2013 report amounted to DKK -2,342,196.
- Gross Profit
- DKK -952,851
- Profit/Loss
- DKK -1,061,402
- Equity
- DKK -2,342,196
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2013
As of December 16, 2013, Jørn Frederik Falch has joined the board of directors of SYNACT PHARMA ApS.
As of December 16, 2013, Uli Alf Hacksell has joined the board of directors of SYNACT PHARMA ApS.
SYNACT PHARMA ApS has published its interim report for the period March 14, 2012 – December 31, 2012.
About SYNACT PHARMA ApS
SYNACT PHARMA ApS is a Danish company of the type Anpartsselskab based in Holte, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named SYNACTION PHARMA ApS. The management consists of Jeppe Øvli Øvlesen, Thomas Boesen and Ann Kristin Brøgger Led. The company is owned by SynAct Pharma AB. In 2025, the company reported a gross profit of DKK -53,194,923 and a net result of DKK -59,812,937 compared with DKK -30,477,376 the year before. Equity in the 2025 report amounted to DKK 20,295,649.